Core Viewpoint - Ensign Group (ENSG) shares have recently declined by 6% over the past week, but the formation of a hammer chart pattern suggests potential support and a possible trend reversal in the future [1]. Technical Analysis - The hammer chart pattern indicates a small candle body with a long lower wick, suggesting that the stock found support after a downtrend, which may signal a loss of control by bears and a potential trend reversal [2]. - Hammer patterns can occur across various timeframes and are utilized by both short-term and long-term investors, although they should be used in conjunction with other bullish indicators for confirmation [2]. Fundamental Analysis - Recent upward revisions in earnings estimates for ENSG are viewed as a bullish indicator, with a 0.1% increase in the consensus EPS estimate over the last 30 days, indicating analysts expect better earnings than previously predicted [4]. - ENSG holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which historically outperform the market [4]. - The Zacks Rank serves as a timing indicator, suggesting that the company's prospects are beginning to improve, further supporting the potential for a turnaround in ENSG shares [4].

Group 1: Ensign Group's Acquisition Strategy - Ensign Group has expanded its portfolio to include 330 healthcare operations across 16 states, with 32 of these also featuring senior living operations [1][9] - The company is acquiring eight healthcare facilities in Alaska, Washington, Oregon, and California, enhancing its geographic reach and diversifying its portfolio [3][9] - The acquisitions are expected to provide high-quality assets and create operational efficiencies through the establishment of clusters in emerging markets [5][10] Group 2: Financial Performance and Projections - Ensign's earnings per share (EPS) for 2024 is forecasted to be between $5.46 and $5.52, indicating a growth of over 15.1% from the 2023 figure of $4.77 [10] - The company has seen a 10.9% increase in shares over the past three months, outperforming the industry average growth of 2.7% [11] Group 3: Market Position and Competitors - Ensign Group is committed to acquiring both successful and struggling healthcare operations, which is expected to drive revenue growth through higher occupancy rates and patient days [10] - Other top-ranked stocks in the medical space include Doximity, CareDx, and Abbott Laboratories, with Doximity currently holding a Zacks Rank 1 (Strong Buy) [12]

SAN JUAN CAPISTRANO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (NASDAQ:ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it has agreed to acquire eight facilities in the states of Alaska, Washington, Oregon, and California, subject to the completion of certain regulatory appro ...

The Ensign Group, Inc.'s (ENSG) board of directors recently approved a 4.2% hike in its quarterly cash dividend to boost shareholders' value. The increased dividend is 6.25 cents per share compared with the previous payout of 6 cents. It will be paid out on or before Jan. 31, 2025, to shareholders of record as of Dec. 31, 2024.This marks the 22nd consecutive year of dividend increases for ENSG. Based on the Dec. 13 closing stock price of $142.42, the new dividend yield is 0.17%, slightly above the industry ...

SAN JUAN CAPISTRANO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it has declared a quarterly cash dividend of $0.0625 per share of Ensign common stock, payable on or before January 31, 2025, to shareholders of record as ...

The Ensign Group, Inc. (ENSG) is benefiting from improved service revenues, a series of acquisitions and a strong financial position. An optimistic 2024 business outlook also reinforces investors’ confidence in the stock.  Zacks Rank & Price PerformanceEnsign Group carries a Zacks Rank #3 (Hold) at present. The stock has gained 33.3% in the past year compared with the industry’s 24.6% growth. The Medical sector and the S&P 500 composite index have increased 2.5% and 30%, respectively, in the same time frame ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores.What a ...

Investors might want to bet on Ensign Group (ENSG) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a cha ...

Core Viewpoint - The Ensign Group, Inc. (ENSG) reported strong third-quarter 2024 results, with a 4.1% increase in shares following the earnings announcement, driven by improved occupancy and higher skilled service revenues, although offset by rising expenses and declining cash flow from operations [1][2]. Financial Performance - Adjusted earnings per share (EPS) for Q3 2024 was $1.39, exceeding the Zacks Consensus Estimate by 1.5% and reflecting a 15.8% year-over-year increase [2]. - Operating revenues reached $1.08 billion, marking a 15% year-over-year improvement and surpassing the consensus estimate by 1.7% [2]. - Adjusted net income grew 17.7% year over year to $81.1 million, beating the estimate of $79.4 million [3]. Operational Metrics - Same-store occupancy improved by 280 basis points year over year, while transitioning occupancy expanded by 480 basis points [3]. - Total expenses increased by 15.3% year over year to $992.4 million, exceeding the estimate of $975.7 million, driven by higher service costs and administrative expenses [4]. Segment Performance - Skilled Services segment revenues rose 14.4% year over year to $1 billion, supported by improved occupancy and patient days, with segment income increasing by 9.1% to $128.5 million [5]. - Rental revenues in the Standard Bearer segment amounted to $24.4 million, growing 16.4% year over year, and segmental income rose 1.5% to $7.3 million [6]. Financial Position - As of September 30, 2024, cash and cash equivalents stood at $532.1 million, a 4.4% increase from the end of 2023, with total assets rising 10.8% to $4.6 billion [7]. - Long-term debt (less current maturities) decreased by 2% to $142.6 million, while total equity climbed nearly 16.9% to $1.8 billion [8]. Capital Deployment - No share buybacks occurred in the first nine months of 2024, while dividends paid amounted to $10.2 million [9]. 2024 Outlook - Revenue guidance for 2024 is projected between $4.25 billion and $4.26 billion, indicating a 14.1% improvement from 2023 [10]. - Adjusted EPS is forecasted to be between $5.46 and $5.52, suggesting over 15.1% growth from the previous year [10].

The Ensign Group, Inc. ENSG reported worse-than-expected third-quarter adjusted EPS results and narrowed its FY24 EPS guidance, after the closing bell on Thursday. Ensign Group reported quarterly earnings of S1.34 per share which missed the analyst consensus estimate of S1.38 per share. The company reported quarterly sales of $1.081 billion which beat the analyst consensus estimate of $1.068 billion. "Our local leaders continue to consistently drive outstanding clinical and financial performance and we are ...